



Executive Summary of Joint Working Outputs
 Published on www.bayer.co.uk

Project Title	Improving Prostate Cancer Services at MVCC – IPCS Project
Duration	January 2023 to June 2024
Project Partners	Mount Vernon Cancer Centre, Northwick Park Hospital and Bayer
What was the issue to be addressed?	The Mount Vernon Cancer Centre has a population of two million in its catchment area and 1750 patients being treated annually for prostate cancer. Given the high demand, the prostate cancer pathway is stretched for resources. The project was set up to increase capacity in the pathway. Through redesigning the out-patient service, patients could be identified before they become metastatic and therefore access treatment in the pathway. The redesign would achieve this through the set up and implementation of two additional specialist oncology pharmacist and non-medical prescriber (NMP) led out-patient clinics.
What was the intervention?	<p>Working together, Mount Vernon Cancer Centre and Bayer implemented the two new clinics, one based at the Mount Vernon Cancer Centre and the second one at London North West University Healthcare (LNWH) Northwick Park Hospital. Out-patient clinics had become oversubscribed resulting in reduced consultant clinic time slots that were not long enough to conduct in depth patient consultations. The project introduced two additional clinics to address this, providing Specialist Oncology Pharmacy Non-Medical Prescriber led out-patient clinics for less complex non-metastatic and metastatic prostate cancer patients receiving systemic anticancer treatment. This freed up time for consultants to see more complex cases and developed a service that will enable patients to be seen in the right clinic according to their needs (complexity level).</p> <p>The addition of two further clinics also had wider aims:</p> <ul style="list-style-type: none"> • Increase rapid access to prostate cancer services by increasing the number of available appointments per week • Improve prostate cancer patients’ awareness of service options available through more detailed patient communications. • Create a thorough understanding of patient disease state and aid self-management and adherence to treatment through improved patient counselling by a non-medical prescribing pharmacist. • Deliver treatment closer to home for prostate patients by allowing patients to access treatment at a hospital site closer to home.
What were the results?	<p>The project has recently completed in June 2024 and has been evaluated and the following measures of success have been highlighted:</p> <ul style="list-style-type: none"> • The additional NMP clinic increased capacity in the service with the NMP pharmacist reviewing 30 patients per week at MVCC, resulting an increase in 370 clinic slots per annum in the prostate clinic.

	<ul style="list-style-type: none">• Healthcare professionals surveyed gained greater knowledge of the role of NMP pharmacists as well as agreeing on the benefit the NMPs bring. At the end of the project, 100% of HCPs surveyed felt that the NMP role would increase capacity and 86% said that their personal workload would decrease.• Within the patient groups surveyed, there was an increase in the number of people saying they felt an NMP can undertake clinical consultations following the project as well as an increase in patients saying that NMPs can prescribe anti-cancer treatments. More patients felt that they received as much information about their treatment as they expected.• There is likely to be even greater improvements in the patient understanding of the NMP as they become more established within the prostate team.• Resources are being produced to support others in developing Business Cases for this model, especially for implementation of outreach clinics.
--	--